Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Bjorn Ringstad

Internal Medicine North Haven, CT Medical Doctor

NPI 1699707448 CMS profile 31353

12 Village St, Suite 5, North Haven, CT 06473

Open in the dashboard

General payments

$1,883

127 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Bjorn Ringstad of North Haven, CT is reported in the CMS Open Payments database as having received $1,883 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $293 18
2019 General $1,590 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bjorn Ringstad
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bjorn Ringstad were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bjorn Ringstad Internal Medicine median Middle half National median
2019 $1,590 $159 $48–$570 $163
2020 $293 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Lilly USA, LLC $244 18 payments
  2. Novo Nordisk Inc $239 12 payments
  3. AstraZeneca Pharmaceuticals LP $199 15 payments
  4. Pfizer Inc. $169 13 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $159 13 payments
  6. Amarin Pharma Inc. $147 12 payments
  7. Sanofi-Aventis U.S. LLC $143 9 payments
  8. Amgen Inc. $132 9 payments
  9. Astellas Pharma US Inc $83 4 payments
  10. Novartis Pharmaceuticals Corporation $62 4 payments
  11. Other $306 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $1,863 124 payments
  2. Education $20 3 payments
Products named General payments · program years 2019–2020
  1. Ozempic $155 8 payments
  2. COLOGUARD $153 11 payments
  3. FARXIGA $150 11 payments
  4. Vascepa $134 11 payments
  5. Repatha $132 9 payments
  6. TRULICITY $128 9 payments
  7. SPIRIVA RESPIMAT $128 14 payments
  8. TOUJEO $128 8 payments
  9. CHANTIX $122 10 payments
  10. JARDIANCE $108 8 payments
  11. Other $1,208 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,751

Median for Internal Medicine: 777

Drug cost

$161,182

Median for Internal Medicine: $73,373

Branded share of claims

12.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $37,064
Trulicity Dulaglutide Brand 25 $35,821
Ozempic Semaglutide Brand 17 $30,075
Farxiga Dapagliflozin Propanediol Brand 15 $19,024
Januvia Sitagliptin Phosphate Brand 13 $17,291
Atorvastatin Calcium Generic 261 $2,857
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $2,454
Levothyroxine Sodium Generic 124 $1,487
Nebivolol Hcl Generic 19 $949
Rosuvastatin Calcium Generic 86 $940

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$5,294

Medicare's payments for the services billed

Medicare patients

82

Average age 78

Services billed

234

40 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Chronic kidney disease 28%
Diabetes 27%
Ischemic heart disease 26%
Atrial fibrillation 26%
Heart failure 22%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record